The FDA approved Moderna's mFlusiva, the first-ever mRNA-based seasonal flu vaccine, marking a historic expansion of the technology that transformed COVID-19 vaccination. The vaccine, approved for adults 50 and older, demonstrated a 26.6% relative efficacy improvement over standard flu shots in a Phase 3 trial of over 19,000 participants.

Vital Signs

• 26.6% — relative vaccine efficacy vs. standard flu shots in adults 50+
• 27.4% — efficacy in adults 65+ (19,000+...